Allakos. has filed a patent for a liquid formulation containing a monoclonal antibody targeting human Siglec-8 for subcutaneous administration. The composition includes specific concentrations of the antibody, histidine or sodium acetate, and maintains a pH between 5.0 and 6.3. GlobalData’s report on Allakos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Allakos, Peptide pharmacophores was a key innovation area identified from patents. Allakos's grant share as of January 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Monoclonal antibody liquid formulation for subcutaneous administration
The patent application (Publication Number: US20230406920A1) describes a liquid formulation containing a monoclonal antibody that binds to a human Siglec-8, with specific concentrations of the antibody and histidine or sodium acetate, maintaining a pH range between 5.0 and 6.3. The antibody's composition includes specific amino acid sequences for the heavy and light chain variable regions, ensuring its efficacy and specificity.
Furthermore, the formulation includes additional components such as sucrose, trehalose, and polysorbate 80 in specific concentrations to enhance stability and efficacy. The patent also details variations in the antibody's structure, including engineered modifications to improve antibody-dependent cell-mediated cytotoxicity (ADCC) activity. These modifications aim to enhance the antibody's therapeutic potential and specificity for targeting Siglec-8, a protein associated with certain diseases. The patent application provides a comprehensive overview of the liquid formulation's composition and the antibody's specific characteristics, highlighting its potential applications in the field of biopharmaceuticals.
To know more about GlobalData’s detailed insights on Allakos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
